Home/ Stocks/ BRTX

BioRestorative Therapies, Inc. Common Stock (NV)

BRTX XNAS

$2.27 -0.06 (-2.58%) ▼ 15-min delayed

Open

$2.28

High

$2.47

Low

$2.25

Volume

21.5K

Market Cap

$3.22M

About BioRestorative Therapies, Inc. Common Stock (NV)

BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving adult stem cells. The company is pursuing its Disc/Spine Program with initial investigational therapeutic product being called BRTX-100 in the treatment of chronic cervical discogenic pain. The technology is an stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot. It is also developing ThermoStem Program, a pre-clinical program which involves the use of brown adipose (fat) in connection with the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.

Sector: SERVICES-MISC HEALTH & ALLIED SERVICES, NEC Employees: 14 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$23.2K	$-2,154,405	$-0.12
FY 2025	$359.7K	$-14,241,975	$-1.58
Q3 2025	$11.8K	$-3,038,277	$-0.33
Q2 2025	$303.3K	$-2,656,263	$-0.30

Earnings & Analyst Ratings

Next Earnings: Tue, Nov 10, 2026

Calendar →

Related Market News

No specific coverage for BRTX yet. Check out our latest market news or earnings calendar.

Get BRTX Alerts

Stay ahead with breaking news, price alerts, and expert analysis on BioRestorative Therapies, Inc. Common Stock (NV).

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.